BMS641

BMS641
Identifiers
	IUPAC name 3-chloro-4-[(E)-2-(5,5-dimethyl-8-phenyl-6H-naphthalen-2-yl)ethenyl]benzoic acid;
CAS Number	369364-50-1;
PubChem CID	22737393;
IUPHAR/BPS	2651;
ChemSpider	11612973;
ChEBI	CHEBI:230489;
PDB ligand	JYI (PDBe, RCSB PDB);
Chemical and physical data
Formula	C27H23ClO2
Molar mass	414.93 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(CC=C(C2=C1C=CC(=C2)/C=C/C3=C(C=C(C=C3)C(=O)O)Cl)C4=CC=CC=C4)C;
	InChI InChI=1S/C27H23ClO2/c1-27(2)15-14-22(19-6-4-3-5-7-19)23-16-18(9-13-24(23)27)8-10-20-11-12-21(26(29)30)17-25(20)28/h3-14,16-17H,15H2,1-2H3,(H,29,30)/b10-8+; Key:FRTYVAKGTFXRNY-CSKARUKUSA-N;

BMS641 (BMS-209641) is a drug which acts as a retinoic acid receptor β (RARβ) agonist. It is used for research into the function of RARβ in roles such as tissue differentiation during embryonic development, and the development of some forms of cancer.^[1]^[2]^[3]^[4]

References

↑ Idres N, Marill J, Chabot GG (1 June 2005). "Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells". Biochemical Pharmacology. 69 (11): 1595–1601. doi:10.1016/j.bcp.2005.02.024. PMID 15896339.
↑ Nadendla E, Teyssier C, Delfosse V, Vivat V, Krishnasamy G, Gronemeyer H, et al. (1 May 2015). "An Unexpected Mode Of Binding Defines BMS948 as A Full Retinoic Acid Receptor β (RARβ, NR1B2) Selective Agonist". PLOS ONE. 10 (5) e0123195. doi:10.1371/journal.pone.0123195. PMC 4416907. PMID 25933005.
↑ Koshy A, Mathieux E, Stüder F, Bramoulle A, Lieb M, Colombo BM, et al. (29 November 2022). "Synergistic activation of RARβ and RARγ nuclear receptors restores cell specialization during stem cell differentiation by hijacking RARα-controlled programs". Life Science Alliance. 6 (2) e202201627. doi:10.26508/lsa.202201627. PMC 9711859. PMID 36446525.
↑ Galindo-Albarrán A, Koshy A, Mendoza-Ferri MG, Mendoza-Parra MA (April 2025). "Decoding transcriptional identity during neuron-astroglia cell fate driven by RAR-specific agonists". NAR Molecular Medicine. 2 (2) ugaf018. doi:10.1093/narmme/ugaf018. PMC 12430019. PMID 41255712.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

[1] Idres N, Marill J, Chabot GG (1 June 2005). "Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells". Biochemical Pharmacology. 69 (11): 1595–1601. doi:10.1016/j.bcp.2005.02.024. PMID 15896339.

[2] Nadendla E, Teyssier C, Delfosse V, Vivat V, Krishnasamy G, Gronemeyer H, et al. (1 May 2015). "An Unexpected Mode Of Binding Defines BMS948 as A Full Retinoic Acid Receptor β (RARβ, NR1B2) Selective Agonist". PLOS ONE. 10 (5) e0123195. doi:10.1371/journal.pone.0123195. PMC 4416907. PMID 25933005.

[3] Koshy A, Mathieux E, Stüder F, Bramoulle A, Lieb M, Colombo BM, et al. (29 November 2022). "Synergistic activation of RARβ and RARγ nuclear receptors restores cell specialization during stem cell differentiation by hijacking RARα-controlled programs". Life Science Alliance. 6 (2) e202201627. doi:10.26508/lsa.202201627. PMC 9711859. PMID 36446525.

[4] Galindo-Albarrán A, Koshy A, Mendoza-Ferri MG, Mendoza-Parra MA (April 2025). "Decoding transcriptional identity during neuron-astroglia cell fate driven by RAR-specific agonists". NAR Molecular Medicine. 2 (2) ugaf018. doi:10.1093/narmme/ugaf018. PMC 12430019. PMID 41255712.

[1]

[2]

[3]

[4]

A page that knows where it met you.

References